scholarly journals Development Of A Global Economic Model To Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment

2014 ◽  
Vol 17 (7) ◽  
pp. A561
Author(s):  
K. Mathurin ◽  
C. Beauchemin ◽  
J. Lachaine
Keyword(s):  
Cost Effectiveness ◽  
Cancer Treatment ◽  
Economic Model ◽  
Metastatic Cancer ◽  
Companion Diagnostics ◽  
Targeted Treatments ◽  
The Cost

scholarly journals The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes

BMJ Open ◽  
2015 ◽  
Vol 5 (5) ◽  
pp. e006535-e006535 ◽  
Author(s):  
T. Butt ◽  
A. Lee ◽  
C. Lee ◽  
A. Tufail ◽  
W. Xing ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Real World ◽  
Economic Model ◽  
Neovascular Amd ◽  
The Cost ◽  
Good Vision

scholarly journals Protocol for the economic evaluation of metacognitive therapy for cardiac rehabilitation participants with symptoms of anxiety and/or depression

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e035552
Author(s):  
Gemma E Shields ◽  
Adrian Wells ◽  
Patrick Doherty ◽  
David Reeves ◽  
Lora Capobianco ◽  
...  
Keyword(s):  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Cardiac Rehabilitation ◽  
Resource Use ◽  
Economic Model ◽  
Metacognitive Therapy ◽  
Trial Analysis ◽  
Health And Social Care ◽  
The Cost

IntroductionCardiac rehabilitation (CR) is offered to reduce the risk of further cardiac events and to improve patients’ health and quality of life following a cardiac event. Psychological care is a common component of CR as symptoms of depression and/or anxiety are more prevalent in this population, however evidence for the cost-effectiveness of current interventions is limited. Metacognitive therapy (MCT), is a recent treatment development that is effective in treating anxiety and depression in mental health settings and is being evaluated in CR patients. This protocol describes the planned approach to the economic evaluation of MCT for CR patients.Methods and analysisThe economic evaluation work will consist of a within-trial analysis and an economic model. The PATHWAY Group MCT study has been prospectively designed to collect comprehensive self-reported resource use and health outcome data, including the EQ-5D, within a randomised controlled trial study design (UK Clinical Trials Gateway). A within-trial economic evaluation and economic model will compare the cost-effectiveness of MCT plus usual care (UC) to UC, from a health and social care perspective in the UK. The within-trial analysis will use intention-to-treat and estimate total costs and quality-adjusted life-years (QALYs) for the trial follow-up. Single imputation will be used to impute missing baseline variables. Multiple imputation will be used to impute values missing at follow-up. Items of resource use will be multiplied by published national healthcare costs. Regression analysis will be used to estimate net costs and net QALYs and these estimates will be bootstrapped to generate 10 000 net pairs of costs and QALYs to inform the probability of cost-effectiveness. A decision analytical economic model will be developed to synthesise trial data with the published literature over a longer time frame. Sensitivity analysis will explore uncertainty. Guidance of the methods for economic models will be followed and dissemination will adhere to reporting guidelines.Ethics and disseminationThe economic evaluation includes a within-trial analysis. The trial which included the collection of this data was reviewed and approved by Ethics. Ethics approval was obtained by the Preston Research Ethics Committee (project ID 156862). The modelling analysis is not applicable for Ethics as it will use data from the trial (secondary analysis) and the published literature. Results of the main trial and economic evaluation will be published in the peer-reviewed National Institute for Health Research (NIHR) journals library (Programme Grants for Applied Research), submitted to a peer-reviewed journal and presented at appropriate conferences.Trial registration numberISRCTN74643496; Pre-results.

scholarly journals A Global Economic Model to Assess the Cost Effectiveness of New Treatments for Advanced Breast Cancer in Canada

2016 ◽  
Vol 19 (3) ◽  
pp. A151
Author(s):  
C Beauchemin ◽  
N Letarte ◽  
K Mathurin ◽  
L Yelle ◽  
J Lachaine
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Advanced Breast Cancer ◽  
Economic Model ◽  
Advanced Breast ◽  
New Treatments ◽  
The Cost

scholarly journals How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mikyung Kelly Seo ◽  
John Cairns
Keyword(s):  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Cochrane Library ◽  
Economic Evaluations ◽  
Health State ◽  
Cancer Therapies ◽  
Companion Diagnostics ◽  
Targeted Cancer Therapies ◽  
Biomarker Testing ◽  
The Cost

Abstract Background Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different cost-effectiveness results. This study aims to examine current practices of modeling companion biomarkers when assessing the cost-effectiveness of targeted cancer therapies. It investigates the current methods in modeling the characteristics of companion diagnostics based on existing economic evaluations of biomarker-guided therapies in cancer. Methods A literature search was performed using Medline, Embase, EconLit, Cochrane library for economic evaluations of biomarker-guided therapies with companion diagnostics in cancer. Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Studies were selected using pre-specified eligibility criteria based on the PICO framework. To make the included studies more comparable, we qualitatively synthesized the data under nine domains of methods where consensus was deemed lacking. Results Only four of the twenty-two studies included in this review were found to be of good quality with respect to incorporating the characteristics of companion biomarkers in economic evaluations. However, many evaluations focused on a pre-selected patient group rather than including all patients regardless of their biomarker status. Companion biomarker characteristics captured in evaluations were often limited to the cost or the accuracy of the test. Often, only the costs of biomarker testing were modelled. Clinical outcomes and health state utilities were often not included due to the limited data generated by clinical trials. Methods of economic evaluation were not applied consistently in assessments of companion cancer biomarkers for targeted therapies. It was also shown that conflicting cost-effectiveness results were likely depending on what comparator arm was chosen and what comparison structure was designed in the model. Conclusion We found no consistent approach applied in assessing the value of companion biomarker tests and including the characteristics of biomarkers in an economic evaluation of targeted oncology therapies. Currently, many economic evaluations fail to capture the full value of companion biomarkers beyond sensitivity/specificity and cost related to biomarker testing.

Sign in / Sign up

Export Citation Format

Share Document